French biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
Antibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
Glucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
Dutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar, which is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
German pharma company Boehringer Ingelheim said the phase II trial for candidate drug BI456906 is expected to be initiated in late 2019 triggering a €20m milestone payment to Zealand Pharma A/S.
Results presented at European Society of Cardiology Congress 2019 demonstrate a new disease mechanism predicting acute organ dysfunction in heart failure patients.